Zura Bio Limited carries no debt; cash flow comfortably covers obligations.

Zura Bio Limited's free cash flow has decreased 130.64% from $-28.15M last year to $-64.93M, signaling decreasing performance

Zura Bio Limited's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Zura Bio Limited has insufficient data to evaluate this check.

Zura Bio Limited has a net cash position, so leverage is healthy.

Zura Bio Limited earns at least as much interest as it pays. Interest obligations are fully covered.

Zura Bio Limited has insufficient data to evaluate this check.

Zura Bio Limited's short-term assets of $112.31M exceed its short-term liabilities of $12.41M

Zura Bio Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Zura Bio Limited's return on equity of -54.98%, is lower than 15.00%, indicating bad performance

Zura Bio Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Zura Bio Limited has insufficient public price history to evaluate earnings stability.

Zura Bio Limited has negative free cash flow, indicating the company is burning cash rather than generating it

Zura Bio Limited has negative free cash flow, indicating cash burn

Zura Bio Limited's yearly earnings has decreased 31.00% since last year from $-52.40M to $-68.65M, signaling decreasing performance

Zura Bio Limited's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -47.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Zura Bio Limited has insufficient revenue history to calculate 3-year revenue CAGR.

Zura Bio Limited has insufficient public price history to evaluate revenue consistency.

Zura Bio Limited has insufficient public price history to evaluate ROE consistency.

Zura Bio Limited has insufficient data to evaluate this check.

Zura Bio Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zura Bio Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Zura Bio Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Zura Bio Limited has insufficient data to evaluate this check.

Zura Bio Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zura Bio Limited has a price-to-book ratio of 3.62x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Zura Bio Limited has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue